<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257592</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00037683</org_study_id>
    <nct_id>NCT03257592</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States</brief_title>
  <official_title>PET Imaging of Glial Activation in Psychotic Disease States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many neurological diseases, including AIDS dementia, Alzheimer's disease and schizophrenia,&#xD;
      involve an inflammatory component thought to specifically involve glial cell activation. The&#xD;
      Investigators has been concerned with the development of tools for noninvasive imaging of&#xD;
      inflammatory processes in psychotic disease. Here, the investigators aim to use PET-based&#xD;
      neuroimaging with carbon-11&#xD;
      N,N-diethyl-2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-acetamide,&#xD;
      ([11C]DPA)-713 to quantify regional distribution of translocator protein (TSPO), a putative&#xD;
      marker of inflammation, in the brains of patients with schizophrenia and bipolar disorder,&#xD;
      type I. The investigators will focus on patients in the early stages of disease (within first&#xD;
      five years of onset of schizophrenia diagnosis and within first five years of first manis,&#xD;
      respectively) to minimize the confounds of age-, chronic illness-, and medication- effects on&#xD;
      our results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of ([11C]DPA)-713 PET brain imaging in patients with recent onset schizophrenia and in patients with recent onset of mania</measure>
    <time_frame>within five years of onset of schizophrenia or within five years of first manic episode</time_frame>
    <description>To determine regional brain uptake of this radioligand in patients with recent onset schizophrenia and in patients with recent onset of mania</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET Imaging of microglial activation</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate changes in activation of microglia in patients with acute schizophrenia and bipolar disorder relative to controls</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Patients with Schizophrenia Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Bipolar Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Bipolar Disorder will be imaged with [11C] DPA-713</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal volunteers will be imaged with [11C] DPA-713</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]DPA-713</intervention_name>
    <description>[11C]DPA-713 PET imaging</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patients with Bipolar Disorder</arm_group_label>
    <arm_group_label>Patients with Schizophrenia Disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers 18-65 years of age&#xD;
&#xD;
          -  Patients diagnosed with recent onset schizophrenia (within 5 years of onset), 18-65&#xD;
             years of age&#xD;
&#xD;
          -  Patients diagnosed with recent onset bipolar disorder (within 5 years of onset of&#xD;
             first mania), 18-65 years of age&#xD;
&#xD;
          -  screening laboratory tests will be obtained for subjects within a 10 day period prior&#xD;
             to the PET study and the results must be within normal limits for gender and age.&#xD;
             These tests will be repeated with a 7-day window following the PET study&#xD;
&#xD;
          -  EKG conducted within 10 day period prior to the PET study. The EKG will be repeated&#xD;
             within 7 days following the study.&#xD;
&#xD;
          -  Subject agrees to return to the Hospital for a follow-up EKG and laboratory testing of&#xD;
             blood and urine.&#xD;
&#xD;
          -  For females of childbearing potential, negative serum pregnancy test within a 10 day&#xD;
             period prior to PET study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of recent nosocomial infection,&#xD;
&#xD;
          -  history of chronic neurological disorder, such as multiple sclerosis or epilepsy, or&#xD;
             structural,central nervous system (CNS) abnormality such as stroke or arteriovenous&#xD;
             malformation,&#xD;
&#xD;
          -  history of head injury with loss of consciousness &gt; 1 hour,&#xD;
&#xD;
          -  history of active substance abuse as defined by substance abuse including alcohol&#xD;
             abuse over the 6 months prior to the study,&#xD;
&#xD;
          -  dependence on benzodiazepine medication&#xD;
&#xD;
          -  contraindications to MRI scanning to include pacemakers, metallic implants/prosthesis&#xD;
             or prohibitive claustrophobia, etc.&#xD;
&#xD;
          -  contraindications to PET scanning to include pregnancy, etc. For females of&#xD;
             childbearing potential, negative serum pregnancy test less than 10 days prior to PET&#xD;
             study&#xD;
&#xD;
          -  ECG demonstrating the patient is not in a sinus rhythm or is having acute ischemia.&#xD;
&#xD;
          -  any medical condition that in the opinion of the study investigators would constitute&#xD;
             a safety risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Pomper, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

